Abstract:Rotavirus causes life-threatening diarrhea in children, resulting in ∼200,000 deaths/year. The current treatment during infection is Oral Rehydration Solution which successfully replenishes fluids but does not alleviate diarrhea volume or severity. As a result, there is an urgent need to better understand rotavirus pathophysiology and develop more effective pediatric therapeutics. Rotavirus primarily infects the tips of small intestinal villi, yet has far-reaching effects on cell types distant from infected cells. We recently identified that rotavirus infected cells release the purinergic signaling molecule ADP, which activates P2Y1 receptors on nearby uninfected cells . To elucidate the role of purinergic signaling via P2Y1 receptors during rotavirus infection , we used the mouse-like rotavirus strain D6/2 which generates a severe infection in mice. C57BL/6J mouse pups were given an oral gavage of D6/2 rotavirus and assessed over the course of 5-7 days. Beginning at day 1 post infection, infected pups were treated daily by oral gavage with saline or 4 mg/kg MRS2500, a selective P2Y1 antagonist. Mice were monitored for diarrhea severity, diarrhea incidence, and viral shedding. Neonatal mice were euthanized at days 3 and 5 post-infection and small intestine was collected to observe infection. MRS2500 treatment decreased the severity, prevalence, and incidence of rotavirus diarrhea. Viral stool shedding, assessed by qPCR for rotavirus gene levels, revealed that MRS2500 treated pups had significantly lower viral shedding starting at day 4 post infection compared to saline treated pups, which suggests P2Y1 signaling may enhance rotavirus replication. Finally, we found that inhibition of P2Y1 with MRS2500 limited transmitted rotavirus diarrhea to uninfected pups within a litter. Together, these results suggest that P2Y1 signaling is involved in the pathogenesis of a homologous murine rotavirus strain, making P2Y1 receptors a promising anti-diarrheal, anti-viral therapeutic target to reduce rotavirus disease burden.

Suppression of Pyrimidine Biosynthesis by Targeting DHODH Enzyme Robustly Inhibits Rotavirus Replication.

PI3K-Akt-mTOR Axis Sustains Rotavirus Infection Via the 4E-BP1 Mediated Autophagy Pathway and Represents an Antiviral Target

ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation

Metformin Hydrochloride Significantly Inhibits Rotavirus Infection in Caco2 Cell Line, Intestinal Organoids, and Mice

Purinergic Signaling Drives Multiple Aspects of Rotavirus Pathophysiology

Quercetin, a flavonoid, combats rotavirus infection by deactivating rotavirus-induced pro-survival NF-κB pathway

Mycophenolic Acid Potently Inhibits Rotavirus Infection with a High Barrier to Resistance Development

Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids

In vitro antiviral activity of abietane diterpenoids isolated from Torreya nucifera against rotavirus infection

6-Thioguanine Inhibits Rotavirus Replication Through Suppression of Rac1 GDP/GTP Cycling.

Modeling Rotavirus Infection and Antiviral Therapy Using Primary Intestinal Organoids

In Vitro Evaluation of Anti-Rotaviral Activity and Intestinal Toxicity of a Phytotherapeutic Prototype of Achyrocline bogotensis (Kunth) DC

ML390 Inhibits Enterovirus 71 Replication by Targeting De Novo Pyrimidine Biosynthesis Pathway.

Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine

The Eukaryotic Translation Initiation Factor 4F Complex Restricts Rotavirus Infection via Regulating the Expression of IRF1 and IRF7

HSP90 inhibitor NVP-HSP990 alleviates rotavirus infection

Bifidobacterium longum and Chlorella sorokiniana Combination Modulates IFN-γ, IL-10, and SOCS3 in Rotavirus-Infected Cells

Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2

A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses

Reverse Genetics Reveals a Role of Rotavirus VP3 Phosphodiesterase Activity in Inhibiting RNase L Signaling and Contributing to Intestinal Viral Replication In Vivo

Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection<i> in</i><i> vitro</i>